益肺止咳胶囊辅助治疗耐药肺结核的临床评价

《益肺止咳胶囊辅助治疗耐药肺结核的临床评价》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、益肺止咳胶囊辅助治疗耐药肺结核的临床评价2009年9月第16卷第17期临床研究益肺止咳胶囊辅助治疗耐药肺结核的临床评价王秀霞(河南省开封市结核病防治研究所药剂科，河南开封475004)【摘要】目的:临床观察益肺止咳胶囊辅助治疗耐药肺结核的疗效.方法:将262例耐药肺结核患者随机分为治疗组132例与对照组130例.治疗组应用益肺止咳胶囊联合抗结核化学纱物进行治疗,对照组只用抗结核化学药物，疗程均为24个月.比较两组强化治疗后和疗程结束时痰菌阴转率和病灶吸收情况以及治疗期间的不良反应情况•结果:强化期结束时治疗组与对照组的痰涂片和痰培养结核杆菌阴转率分别为38%和31%;巩固期结束时分别为71%和

2、62%X线影像学病灶吸收显效率分别是26%和19%;冇效率分别74%和60%;空洞明显缩小或闭合率70%和57%;不良反应发生率分别为18%和44%.统计学分析结果表明治疗组的阴转率和病灶吸收情况优于对照组(P<0.05),治疗组不良反应发生率低于对照组(P<O.05).结论:含益肺止咳胶囊联合抗结核化学药物治疗耐药肺结核的疗效优于单独应用抗结核化学药物,H可降低抗结核化学药物的不良反应，取得较好的疗效,值得在临床上广泛使用.『关键词1益肺止咳胶囊;耐约肺结核;疗效I中图分类号】只521【文献标识码】A【文章编号】1674—4721(2009)09(a)—025—03Clinica

3、levaluationonthetherapeuticeffectofYifeizhikecapsulesondrugresistantpulmonarytuberculosisNGXiux/a(DepartmentofPharmaeeutics,KaifengTuberculosisControlInstitute,Kaifeng475004,China)【Abstract]Objective:Toinvestigatethetherapeuticeffectofthechemotherapycombinedwiththeuseofyifeizhikecap一sIllesondrugresi

4、stantpulmonarytuberculosisfDR-TB).Methods:262casesofpatientswithDR-TBwererandomlydi一videdintotreatmentgroup(132cases)andcontrolgroup(130cases).Thetreatmentgroupwastreatedwithyifeizhikecap一sulesinadditiontotheantitubereuloticchemotherapy.whilethecontrolgroupwastreatedwithantituberculoticchemother—apy

5、only.Thecourseoftreatmentwas24monthsincluding3monthsforreinforeementand21monthsforconsolidation.Clinicaleffectofsputumnegativeconversionrateandimagingabsorptionrateandadversereactionwereinvestigated.Resuits:Afterreinforcedtreatment.thesputumnegativeconversionrateintreatmentandcontroIgroupswere38%an

6、d31%.whilethoseafterconsolidationwere71%and62%,respectively.X-rayieonographyresultsshowedthatexcellentimagingabsorptionratewere26%andl9%,whileeffectiveabsorptionratewere74%and60%,respectively.Thecavitycloggingratewas70%and57%,respectively.Therateofsideeffectswasl8%intreatmentgroup,while44%incontrolg

7、roup.Theclinicalstudyshowedthatthesputumnegativeconversionrateandimagingabsorptionrateintreatmentgroupweresignifi一cantlyhigherthanthoseincontrolgroup(P<0-05),whilesideeffectsrateintreatmentgroupwas